Objective: To describe the systemic effects of high-dose recombinant tumor necrosis factor alpha (rTNF-a), recombinant interferon gamma (rIFN-'y), and melphalan administered through hyperthermic isolation perfusion of the limbs (IPL) 
chanical trauma). They are primarily devoted to transmiting information to other cells. In addition, they are responsible for systemic effects such as induction of fever and stimulation of acute-phase proteins produced by the liver. Some have antiinflammatory effects (interferon [IFN] ; interleukin-6 ), but others are proinflammatory agents, particularly tumor necrosis factor alpha (TNF-a) and interleukin-1 (IL-1). Cytokines appear to be major mediators of the immune response and play a mandatory role in type B and T cellular response. Moreover, large amounts of TNF-a and IL-1 produced in response to microbial products (endotoxin particuSystemic and Hemodynamic Effects of Recombinant TNF-a in Limb Isolation Perfusion (Egg/mann et al) CaO2=arterial content in oxygen; CI=cardiac index; CO=cardiac output; CvO2=venous (pulmonary artery) content in oxygen; CVP=central venous pressure; DIC=dis-seminated intravascular coagulation; Do2=oxygen delivery; FIo2=inspired oxygen fraction; IFN-y=interferon gamma; IPL=isolation perfusion of the limb; IL-l=inter-leukin 1; IL-6 = interleukin 6; IV= intravenous; MOF=multi-ple organ failure; PaO2=arterial oxygen pressure; PCWP=pulmonary capillary wedge pressure; rIFN-'y=re-combinant interferon gamma; rTNF-a=recombinant tumor necrosis factor alpha; SaO2=arterial saturation in oxygen; SpO2=pulse-oximetry saturation in oxygen; Sv02= venous (pulmonary artery) saturation in oxygen; TNFa=tumor necrosis factor alpha; Vo2=oxygen uptake larly) may become central mediators of the systemic reactions such as fever, inflammation, tissue lesions, metabolic dysfunctions, sepsis, septic shock, and multiple organ failure (MOF). '-7 Tumor necrosis factor alpha is a 17-kd polypeptide mainly produced by monocytes and macrophages in response to microorganism products (endotoxin, teichoic acid, exotoxin, and other).8 It is an important mediator of the cardiovascular dysfunction characteristic of sepsis and septic shock.9 '15 In patients with meningococcemia or septic shock, the serum levels of TNF-a have been shown to correlate with survival. [16] [17] [18] [19] An interesting property of TNF-a is the efficient hemorrhagic and coagulative necrosis of transplanted tumors that it produces in animals.20 Phase 1 trials of treatment with recombinant TNF-a (rT-NF-a) (intratumoral, subcutaneously, intramuscularly, or intravenously) have reported promising results in some patients with cancer, consisting of necrosis of the tumor. [21] [22] [23] [24] [25] However, these studies found that severe systemic side effects limited the maximal tolerated dose at about 200 to 400 Ag/m2.
Combined with recombinant human interferongamma (rIFN--y), which increases the number of TNF receptors on tumor cells,22'26'27 the administration of very high doses of both rTNF-a (3 to 4 mg) and melphalan (40 to 120 mg) in hyperthermic isolated limb perfusion (IPL) was recently shown to be active in the treatment of metastatic melanoma or soft-tissue sarcoma. The adverse effects associated with this triple-drug regimen were mild and mainly attributed to TNF-a.28'29 Despite extremely high amounts of bioactive TNF-a released in the circulation from the extravascular compartment after the end of the IPL, followed by a delayed release of high amounts of IL-6, no correlation could be found between TNF-a and the systemic effects observed. 30 Such therapy was recently introduced in our institution and was associated with major side effects. The aim of this retrospective study is to report our experience on the systemic effects of rTNF-a released systemically after IPL.
MATERIAL AND METHODS

Patient Selection
All patients were referred to the Pluridisciplinary Center for Oncology for relapse following conventional therapy for regionally advanced melanoma (stage III A and III AB) or sarcoma. The protocols were approved by the ethical committee of our institution (1,000-bed tertiary-university hospital). After extended workup and oral informed consent, in accordance with the Swiss rules for medical research, the patients were all included in a phase 2 multicentric study. Patients by the manufacturer (Boehringer Ingelheim, Germany). Both were stored as a lyophilized powder that was aseptically reconstituted with 1 mL sterile saline solution. Prior to IPL, all patients received 1.5X106 U IFN-y per day subcutaneously for 2 days before surgery. For the patients assigned to receive the triple-drug regimen containing rIFN-y perfusion, 0.2 mg of the drug was injected in the arterial line at the beginning of the IPL. According to previous procedure.28 4 mg of rTNF-a for a leg or 2 mg for an arm was infused at the arterial line of the IPL when tissue temperature reached 380C. The melphalan dose (Alkeran, Burroughs Wellcome, London, UK) was calculated according to the "liter-volume"3' method to give a plasma concentration at equilibrium of 40 yg/mL, and 33 to 100 mg was administered 30 min later. Indomethacin was administered intravenously (IV) (50 mg over 4 h, followed by 200 mg over the next 20 h) to decrease systemic adverse manifestations.25,32 Just before cannulation of the limb vessels, 200 IU/kg heparin was given IV and a continuous infusion of dopamine (3 to 5 Ag/kg/min) was started, which lasted until the procedure was ended and the patient was transferred from the ICU. These treatments were then maintained until complete recovery and discharge from ICU. The whole perfusion lasted 90 min, and the limb was then washed with a hydroxyethylstarch solution (Haes-steril 6%, Fresenius AG, Stans, Switzerland). Antibiotic prophylaxis consisted of five doses of a firstgeneration cephalosporin.
Type and Technique of Anesthesia and ICU Monitoring
To provide stable hemodynamic parameters for a 6-to 10-h surgical operation, we chose an anesthesia technique similar to that used for cardiac surgery procedures. Induction and maintenance anesthesia consisted of lorazepam or midazolam, fentanyl, and pancuronium. Due to the potential high risk of distributive shock, halogenate agents were not used. Arterial and pulmonary catheters were inserted in all patients after induction of anesthesia and the following parameters were monitored until the end of ICU stay: continuous five-lead ECG; hourly urine output; pulseoximetry (SpO2); systolic (SABP), mean (MABP), and diastolic (DABP) arterial blood pressure, central venous pressure (CVP), mean pulmonary artery pressure (MPAP), and pulmonary capillary wedge pressure (PCWP). Cardiac output (CO) was measured by the thermodilution method in triplicate and pulmonary arterial blood oximetry (SaO2) was determined by Co-oximetry. 33 were considered: (1) distributive shock: a high cardiac index (CI, CO/body surface in mi2) -4.5 L/min/m2 associated with low indexed systemic arterial resistances (SARi=MAP-CVP/CIX 8OXbody surface) < 1,200 dyne -s * cm-5/m2 in patients requiring vasopressor therapy after a sufficient fluid challenge; (2) mixed shock: a normal or low CI <3.0 L/min/m2 associated with low SARi < 1,200 dyne * s -cm-5/m2 in patients requiring a combination of vasopressor and inotropic agents after a sufficient fluid challenge. Oxygen transport parameters were defined as follows: oxygen delivery (Do2 in mL/minXm2) as the product of Cl and arterial content in 02 (CaO2=1.3XHbXSaO2X10); oxygen uptake (Vo2 in mL/min X mi2) as the product of CI and the difference between arterial and venous 02 contents (CvO2= 1.3XHbX SvO2X 10). ARDS was defined as the presence of a low PaO2 (02 inspired fraction ratio [PaO2/FIo2]<120) associated with bilateral pulmonary interstitial or mixed infiltrates in patients with normal or low PCWP (<15 mm Hg).
Postoperative Management
At the end of the operation, all patients were admitted to the surgical ICU, and they were mechanically ventilated until they recovered from anesthesia and were extubated. All the abovementioned parameters were prospectively monitored. The CI and SvO2 were determined at admission, then at 6, 12, 24, and 48 h after the administration of rTNF-a or when indicated by the patient's clinical condition. In all patients, the goal was to maintain CI over 4.5 L/min/m2, Do2 over 600 mL/minXm2, and Vo2 over 170 mL/minXm2.3637 Assessment of Tumor Response Tumor response was assessed using standardized criteria as in our previous study.28 '29 Measurement of TNF-a A highly sensitive mouse fibrosarcoma cell line, WEHI 164 clone 13 (provided by J. Tschopp, Institute of Biochemistry, Lausanne, Switzerland), was used to measure serum TNF-as levels, as originally described by Espevik and Nissen-Meyer. 38 The limit of detection was <0.5 pg/mL.
Data Analysis
The changes in the various parameters throughout the study in the two groups were assessed using nonparametric tests (the Friedman and the Wilcoxon tests), using a software package (Statview, Brainpower, Calabasas, Calif). A p value of <0.05 was considered significant.
RESULTS
Characteristics of Patients
Nineteen patients were included in the study from February 1992 to March 1993. Their characteristics are listed in Table 1 . Thirteen patients suffered from one (or more) associated illnesses that may worsen the systemic response to IPL, the hemodynamic response to IPL, or both, including nine patients with cardiopathies of various origin. The conditions of these patients were well stabilized and they were asymptomatic with adequate therapy. Isolation perfusion of the limb was performed via the iliac vessels in nine patients, the femoral in five, and the subclavian in four. One patient was treated a second time for a regional relapse after 8 months. All patients except one were treated with the triple-drug-regimen consisting of rTNF-a, rIFN-y, and melphalan. The mean stay in the ICU was 98 h (range, 43 3 ; range, 0 to 10 U) and crystalloids/artificial colloids solutions (colloids: mean volume, 1,100 mL; range, 0 to 2,000 mL; crystalloids: mean, 4,100 mL; range, 2,500 to 8,000 mL). One patient required an emergency arterial thrombectomy a few hours after the end of IPL. This was followed by a rhabdomyolysis requiring several fasciotomies. The systemic and hemodynamic responses to rTNF-at following IPL could therefore not be evaluated in this patient, thus leaving 18 evaluable patients.
Patterns of Shock During the Postoperative Period During the early postoperative phase, 17 the 18 evaluable patients (94%) presented a shock unresponsive to fluid challenge, requiring the continuous perfusion of vasopressor or vasopressor and inotropic agents, 1 to 10 h after the administration of rTNF-a through IPL. In one patient, a young athletic man, hypotension responded to a massive fluid challenge only: blood (9 U), fresh frozen plasma (3 U), hydroxyethylstarch (2,000 mL), and crystalloids (8,000 mL). Nine patients had a distributive shock, while a mixed shock was found in eight other patients. Patients with a distributive shock required noradrenaline earlier than those with a mixed shock (4 h vs 61/3 h after rTNF-a), but the ranges did not differ (1 to 11 h vs 2 to 10 h, respectively) ( Table 2 ). In the patients with a mixed shock, dobutamine therapy was required after a mean delay of 9 h (range, 1 to 16 h) after rT-NF-a administration. All patients recovered from their shock within 46 + 22 h, although all had a persistent hyperdynamic state for several additional days (Fig 1) . Delivery, Uptake of Oxygen, and Pulmonary Gas Exchanges The oxygen parameters were mainly characterized by an increase in both Do2 and Vo2. In most patients, the 02 extraction ratio was reduced during the phase of shock, and this abnormality persisted for 24 to 48 h until removal of the pulmonary artery catheter. Patients required mechanical ventilation for a mean of 3 days (range, 1 to 5 days). Transient bilateral interstitial or mixed infiltrates were documented in all patients on the chest radiographs during the first 2 days after IPL. The PaO2/FIo2 ratio was below 200 in seven patients, but none presented the full ARDS criteria.
Other Systemic and Local Effects
Temperature peaked up to 38.4°C in 12 patients (67%) without chills (Table 3) . Fourteen patients (78%) had an initial transient (3 to 6 h) fall in WBC count (<4.0 giga/L), including neutropenia (neutrophils <1.0 giga/L) in 6 of them (43%). Despite severe perturbation of the parameters of coagulation, a disseminated intravascular coagulation (DIC) was documented in one patient only. These hematologic perturbations returned to normal within 72 h, with the exception of the thrombocyte counts that returned to normal after 5 to 7 days only. These alterations were not associated with clinically significant hemorrhage; however, it must be mentioned that all these patients did receive several units of fresh frozen plasma. Nine patients (50%) had some liver toxic reactions, consisting mainly of slight cytolysis or hyperbilirubinemia (Table 3) . Four patients (22%o) had a fall in creatinine clearance, which was transient. Tubular necrosis related to shock did not occur. All perfused limbs presented an important localized reaction characterized by a large lymphedema, diffuse erythema, and progressive necrosis of the tumor.
Development of Infection
An infection requiring a modification of the antibiotic prophylaxis was documented in 11 patients (61%). Six patients developed microbiologically documented bronchopneumonia, characterized by purulent sputum (Gram-negative bacilli in five, Grampositive cocci in one) and a chest radiograph with new infiltrates. In three other patients, bronchopneumonia was diagnosed on clinical gounds only. These episodes were treated with a third-generation cephalosporin or with amoxicillin/clavulanate. Two patients had a superinfection of the necrosed tumor (Pseudomonas aeruginosa in one patient and Staphylococcus aureus in the second).
Circulating TNF-a Levels
Bioactivity of TNF in the blood during the IPL and in the systemic circulation after tourniquet removal were measured in 12 patients (Table 4) . The results demonstrated an early massive leakage from IPL to the systemic circulation. However, no apparent correlation was observed between TNF-a levels measured in the systemic circulation and either the type or the duration of shock. Six of 12 patients had a peak higher than 100,000 pg/mL. The characteristics of the shock in the six patients with levels >100,000 pg/mL did not differ from the characteristics of the other six patients.
DISCUSSION
Major systemic changes were observed in all patients receiving a combination of rTNF-a, rIFN-y, and melphalan in hyperthermic IPL for in transit metastasis of melanoma or sarcoma. These were mainly characterized by acute circulatory failure mimicking septic shock associated with disturbances of gas exchanges, a drop of blood cell counts, and abnormal results liver function tests. Two main mechanisms must be considered to explain these findings: first, the effect of TNF-a, IFN-y, or melphalan during and following IPL, and second the effect of the hyperthermic IPL per se.
Hemodynamic Response
In the present study, all patients had a shock starting soon following cytokine administration. This required immediate and important fluid resuscitation and vasopressor administration. affected by the IPL. The perturbation was characterized by high Do2 and Vo2, associated with low 02 extraction ratio. As for hemodynamics, similar findings are observed during sepsis syndromne and septic shock.43 Interestingly, in our patients, this change in body 02 utilization was more prolonged than the shock period. Since this low 02 extraction ratio was not associated with significant lactic acidosis, it suggests that systemic 02 debt was not prominent.
Systemic Effects of IPL
Hyperthermic IPL has become the established mode of therapy for regionally advanced melanoma and sarcoma. It allows the administration of high doses of drugs in a closed system with acceptable local toxic reactions.44'45 From their cumulative experience on 1,509 courses of chemotherapy through IPL, the group who described the method more than 30 years ago reported some local side effects but very limited systemic effects attributable to this technique. 46 Thus, it is likely that the systemic effects that were observed in the present study could not be attributed either to the hyperthermic IPL or to the melphalan.
Systemic Effects of INF-,y Interferon gamma has direct antiproliferative activity against some human tumor cells lines47'48 and was added for its potential synergy with TNF-a.49 '50 In the present study, the main purpose of its administration was to raise the number of TNF The systemic effects of TNF administration have been well described.35460 In patients with cancer severe systemic effects occurred after the administration of 200 to 300 gg/m2 rTNF-a, and consisted of fever (41 0C), hypotension, dyspnea, abnormalities of the liver function test results, thrombocytopenia, and leukopenia.21-25 Many of the systemic manifestations observed in our patients after high-dose rTNF-a administration through IPL are consistent with these previous observations. The severe distributive shocks observed, requiring aggressive supportive therapy, including very high amounts of fluids and vasopressor, were not unexpected with large TNF leakage. To our knowledge, they have not been reported previously in other published series.28 '29'39 It is well established that among cytokines, TNF-a is one of the major mediators of the cascade of events leading to the multiple dysfunctions related to septic shock.5'6'6' Pretreatment with antibodies against TNF-at has been shown to prevent death in mice and in primates challenged with endotoxin or with live microorganisms.2 '62 In human volunteers challenged with small doses of endotoxin (4 ng/kg), serum TNF levels reached 100 pg/mL.63 In patients with documented septic shock, persistent TNF-a levels of up to 200 to 300 pg/mL correlated with fatal outcome.17 '18 High levels of TNF-a have been reported among patients with fatal meningococcemia (500 to 3,500 pg/mL).16'19 A recent article reported extremely high levels of TNF-at (9,157 pg/mL) in a man who survived to severe shock with mild organ dysfunctions after self administration of 15,000 ng/kg of purified endotoxin.64 The serum levels of TNF-a (1,760 to 365,440 pg/mL) found in our patients at the end of IPL in the systemic circulation are among the highest reported in the literature30'64 and were probably related to rTNF-a release from the limb tissues after the end of IPL. All but one patient developed a septic-like shock, but the absence of correlation between the levels of TNF-a and the systemic effects may indicate that the systemic response to TNF-a could depend on other factors, such as the presence of endotoxin or of other circulating cytokines. 40, 65, 66 None of our patients died. This strongly contrasts with the 50% mortality rate repeatedly reported in patients with detectable levels of circulating TNF-a in septic shock of various causes.67'68 These data suggest that factors other than TNF-at may be responsible for the fatal outcome observed in septic shock.
CONCLUSION
Major systemic effects, consisting mainly of cardiovascular, respiratory, and hematologic disturbances resulted from TNF-a leakage in patients after IPL with high-dose of recombinant TNF-a. Although not correlated with the levels of TNF-a found in the systemic circulation, the most striking side effect consisted of a prolonged septic shock-like syndrome requiring aggressive management. All organ failures resolved within 2 to 5 days and all patients survived without sequelae.
